Molecular Partners (NASDAQ:MOLN – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.08, Zacks reports.
Molecular Partners Stock Up 2.6%
Shares of Molecular Partners stock traded up $0.09 during midday trading on Friday, hitting $3.62. The company had a trading volume of 1,523 shares, compared to its average volume of 4,315. The company has a fifty day simple moving average of $4.05 and a 200 day simple moving average of $4.18. Molecular Partners has a 12-month low of $3.51 and a 12-month high of $5.36. The stock has a market cap of $146.22 million, a price-to-earnings ratio of -2.12 and a beta of 1.11.
Wall Street Analysts Forecast Growth
Several brokerages have commented on MOLN. HC Wainwright restated a “buy” rating on shares of Molecular Partners in a report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, October 2nd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.38.
View Our Latest Analysis on MOLN
About Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.
Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.
Featured Stories
- Five stocks we like better than Molecular Partners
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
